Xilio Therapeutics, Inc. (XLO) stock
XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3080% below fair value
$7.54−0.16 (-2.08%)
Close on Nov 17, 2026Market cap $43.60MP/E –Yield –
Xilio Therapeutics cash
Cash and short-term investments held at the end of each period.
Xilio Therapeutics's cash was $136.04M at Jun 30, 2026. For fiscal 2025 it was $137.53M, up 141.0% from the year before. The highest annual figure on record is $199.61M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $137.53M | +141.0% |
| FY2024 | Dec 31, 2024 | $57.07M | +23.3% |
| FY2023 | Dec 31, 2023 | $46.29M | -62.0% |
| FY2022 | Dec 31, 2022 | $121.95M | -38.9% |
| FY2021 | Dec 31, 2021 | $199.61M | +860.2% |
| FY2020 | Dec 31, 2020 | $20.79M | -57.6% |
| FY2019 | Dec 31, 2019 | $49.04M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $136.04M | +11.9% |
| Q1 FY2026 | Mar 31, 2026 | $150.33M | +68.8% |
| Q4 FY2025 | Dec 31, 2025 | $137.53M | +141.0% |
| Q3 FY2025 | Sep 30, 2025 | $103.76M | +69.4% |
| Q2 FY2025 | Jun 30, 2025 | $121.55M | +62.2% |
| Q1 FY2025 | Mar 31, 2025 | $89.07M | +162.1% |
| Q4 FY2024 | Dec 31, 2024 | $57.07M | +23.3% |
| Q3 FY2024 | Sep 30, 2024 | $61.26M | +2.5% |
| Q2 FY2024 | Jun 30, 2024 | $74.95M | -0.6% |
| Q1 FY2024 | Mar 31, 2024 | $33.98M | -63.6% |
| Q4 FY2023 | Dec 31, 2023 | $46.29M | -62.0% |
| Q3 FY2023 | Sep 30, 2023 | $59.77M | -57.0% |
| Q2 FY2023 | Jun 30, 2023 | $75.38M | -52.7% |
| Q1 FY2023 | Mar 31, 2023 | $93.27M | -47.3% |
| Q4 FY2022 | Dec 31, 2022 | $121.95M | -38.9% |
| Q3 FY2022 | Sep 30, 2022 | $139.14M | +39.5% |
| Q2 FY2022 | Jun 30, 2022 | $159.41M | +32.5% |
| Q1 FY2022 | Mar 31, 2022 | $176.96M | +25.3% |
| Q4 FY2021 | Dec 31, 2021 | $199.61M | +860.2% |
| Q3 FY2021 | Sep 30, 2021 | $99.77M | +198.0% |
| Q2 FY2021 | Jun 30, 2021 | $120.30M | +145.3% |
| Q1 FY2021 | Mar 31, 2021 | $141.22M | – |
| Q4 FY2020 | Dec 31, 2020 | $20.79M | – |
| Q3 FY2020 | Sep 30, 2020 | $33.48M | – |
| Q4 FY2019 | Dec 31, 2019 | $49.04M | – |
See a number that looks wrong?